Ombretta Annibali
0000-0002-3095-5313
11 papers found
Refreshing results…
Lenalidomide plus rituximab for the initial treatment of frail older patients with DLBCL: the FIL_ReRi phase 2 study
High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real‐life experience
Long-term quality of life of patients with acute promyelocytic leukemia treated with arsenic trioxide vs chemotherapy
Alkaline phosphatase (alp) levels in multiple myeloma and solid cancers with bone lesions: Is there any difference?
Early Progression As a Predictor of Survival in Marginal Zone Lymphomas: An Analysis from the FIL-NF10 Study
Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis
Chemotherapy-induced Nausea and Vomiting Prophylaxis in High-dose Melphalan and Autologous Stem Cell Transplantation
PD-1/PD-L1 expression in extra-medullary lesions of multiple myeloma
Review article: Mucosa-associated lymphoid tissue (MALT)-type lymphoma of ocular adnexa. Biology and treatment
Rituximab as Single Agent in Primary MALT Lymphoma of the Ocular Adnexa
Missing publications? Search for publications with a matching author name.